Aims To assess the long-term outcome regarding quality of life and survival in patients who were included in the ESBY study 1992-1995. The ESBY study (Electrical Stimulation versus Coronary Artery Bypass Surgery in Severe Angina Pectoris) included 104 patients -with severe angina, increased surgical risk and no prognostic benefits from revascularization -randomized to coronary artery bypass grafting or spinal cord stimulation.
Introduction
The standard treatments in severe angina pectoris are pharmacological therapy and revascularization procedures, such as coronary artery bypass grafting (CABG) and percutaneous transluminal coronary intervention (PTCI). In contrast to PTCI, improved survival has been shown for selected groups after CABG [1] . However, it can be concluded that both these strategies are effective in reducing symptoms of coronary artery disease [2] [3] [4] . Revascularization is associated with risks, related to the disease itself, the patient, perioperative events and postoperative factors. In a substantial number of patients, CABG and PTCI are hazardous due to coronary anatomy and/or risk factors [5] [6] [7] [8] . For this group, and for patients not accessible to revascularization, other treatment methods can be considered. Spinal cord stimulation (SCS) has been used in patients with severe angina pectoris, and has proven to be a safe treatment method with good short-term and long-term efficacy [9] [10] [11] . It has been concluded that SCS reduces myocardial ischaemia and thereby relieves the anginal pain during cardiac stress [12] [13] [14] [15] [16] [17] [18] [19] . In a previous investigation, the ESBY study (Electrical Stimulation versus Coronary Artery Bypass Surgery in Severe Angina Pectoris) [20] 104 patients with severe angina, increased surgical risk and no proven prognostic benefit from revascularization were included over a period of 3 years during 1992-1995, and randomized to either CABG (n=51) or SCS (n=53). Until the ESBY study was initiated, SCS had been used exclusively to treat angina in patients for whom to revascularization was not accessible. The aim of the ESBY study was to compare the results of SCS and CABG in patients acceptable for CABG, who had an increased intraoperative and postoperative complication risk and no prognostic benefit from CABG, in a randomized prospective trial. The primary goal was to compare the effect on angina, while mortality and morbidity were secondary end points. Anginal symptoms decreased (in terms of attack frequency and consumption of short-acting nitrates) in both groups 6 months after the procedure (P<0·0001), without any significant differences between the groups. At the 6 month follow-up, there was a lower mortality rate and lower cerebrovascular morbidity in the SCS group compared to the CABG group (P<0·02 and P=0·03 respectively) [20] . For patients with severe angina and increased surgical risk it is important to find effective symptom relief with acceptable risks. Long-term follow-up is necessary to ensure the safety, especially for newer and less well documented treatments. It was considered urgent to assess long-term outcome of the newer method (SCS) compared to the standard method (CABG) for these patients.
Thus, the aim of the present study was to assess long-term outcome in terms of quality of life and survival of the patients who were included in the ESBY study; the hypothesis to be tested was that the two treatment methods would be comparable in terms of long-term survival and long-term symptom relief.
Methods

Design
The ESBY study was designed as a randomized, prospective, open comparison between CABG and SCS in patients with severe angina pectoris despite optimal pharmacological treatment. Inclusion was limited to patients with no proven prognostic benefit from CABG and with increased surgical risk (Tables 1 and 2 ). The data were to be analysed on an intention-to-treat basis.
Patients
Patients were included over a period of 36 months, from 1992 to 1995 [20] . All patients were evaluated for revascularization procedures according to the American College of Cardiology/American Heart Association (ACC/AHA) guidelines 1991 [1] , by a team of cardiac surgeons, cardiologists and the referring physicians at the routine revascularization conferences at O } stra Hospital and Sahlgren's Hospital, Gö teborg, Sweden.
Among the 3393 patients who underwent coronary angiography and were evaluated during the inclusion period, 2914 patients (86%) were offered revascularization outside the study (not meeting the study's inclusion criteria) while 375 patients (11%) were not eligible for revascularization. One-hundred-and-four patients (3·1%) met the criteria and gave consent to participation.
Optimal antianginal pharmacological therapy had not provided these patients with satisfactory relief of anginal symptoms, and the patients were eligible for coronary bypass surgery with increased but acceptable risk, corresponding to ACC/AHA indications for intervention with regard to symptomatic benefit [1] . The Ethical Committee of the University of Gö teborg approved the study.
The patients were included after informed consent; 21 women and 83 men, with a mean age of 70·5 (range 40-82) years (Table 3) . Fifty-one patients were randomized to CABG and 53 to SCS. Two of 104 subjects worked full-time, five worked part-time, 21 were on sick leave and 76 had retired. The health-related differences between the groups were negligible except for renal disease and smoking ( Table 3 ). The mean Higgin's score [7] (a scoring system for estimation of pre-operative risk) was just above four and did not differ between the groups. The coronary anatomy is presented in Table 4 . There was no significant difference in medication at run-in between the groups (Table 5) .
SCS implantation technique
The SCS device is implanted under local anaesthesia. The patient is awake, lying in a prone position. After a minor skin incision at the mid-thoracic level, the epidural space is identified, using a Touhy needle and loss-of-resistance technique. Under X-ray monitoring, an electrode is inserted through the needle and is advanced until the tip reaches the level of T1. Proper electrode positioning produces paresthesiae in the chest during intra-operative test stimulation, corresponding to the location of the patient's angina, confirming Table 2 CABG=coronary artery bypass grafting; SCS=spinal cord stimulation. 
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stimulation of the spinal segments of the cardiac innervation. An extension wire is tunnelled subcutaneously to the implantable pulse generator, which is usually placed in a subcutaneous pouch below the costal arch. The system is thus fully implanted, and is programmed telemetrically. The stimulation is switched on and off and increased and decreased by the patient. The stimulation device used at our centre is commercially available (Medtronic).
Quality of life assessment
Perceived quality of life was assessed by means of the 'Nottingham Health Profile' (NHP) [21] and the 'Quality of Life Questionnaire -Angina Pectoris' (QLQ-AP) [22] . QLQ-AP is a disease-specific questionnaire, while NHP is generic, i.e. designed to measure any health-related changes in quality of life.
NHP has been validated and widely used to assess health-related quality of life [23] [24] [25] , and 'reference values' for a healthy population are available [26] . Diseasespecific questionnaires like QLQ-AP are not applicable to a healthy population, and thus do not offer any such 'reference values'. However, it is designed to detect changes in the impact of the disease on quality of life.
The NHP consists of two parts. Part 1 includes 38 statements grouped into six dimensions: energy (three items), pain (eight items), emotional reactions (nine items), sleep (five items), social isolation (five items) and physical mobility (eight items). Part II of the NHP deals with seven aspects of daily life: work, ability to perform tasks in the home, social life, home relationships, sex life, hobbies, and holidays. The higher the score, the greater the impairment of the patient's quality of life. The scores are also adjusted using a weighting system. QLQ-AP assesses the impact of the anginal symptoms on the patient's quality of life. Thus, the questions are put to reveal disease-related problems. Each question offers six different alternatives. The questions are grouped into four different dimensions; emotional distress, somatic symptoms, life satisfaction and physical activity. The lower the score, the greater the impairment of the patient's quality of life.
Data were obtained, on average, 46 days before and 6 months after the intervention. Later, a third follow-up measurement was performed, at median 58 months (4·8 years) after the intervention. One hundred-and-one questionnaires were evaluable at baseline, 90 at the second assessment and 70 at the third assessment. The reasons for missing values are death (n=29), neurological deficit (n=3; dementia, cerebrovascular sequelae, severe Parkinson's disease), and withdrawn patient consent to follow-up (n=2).
Survival data
Data on all-cause mortality were collected from patient records and central registers at the Swedish National Board for Health and Welfare. The inclusion date was considered the starting point for each patient, and data were analysed on an intention-to-treat basis. Three-year and 5-year survivals were analysed.
Statistical methods
The quality of life assessments included three measuring points and consequently an analysis of variance was applied, using repeated measures ANOVA, with the randomization as a grouping variable [27] . A post hoc analysis (Fischer's PLSD (protected least significant difference)) was used to localize significant variations. The survival data were analysed using Kaplan-Meier probabilities and Cox proportional hazard models. A P-value of <0·05 was considered significant. Statistical analysis was performed using Statview 5.0.
Results
Quality of life
In both quality of life assessments there were significant improvements 6 months after SCS/CABG compared to run-in (P<0·001), and the results were consistent after 4·8 years. There were no significant differences between the CABG and the SCS groups, at either run-in or after the procedure (Figs 1 and 2) .
Among the subcategories in NHP, there were significant improvements in 'energy' and 'pain' scores · but without significant differences between SCS and CABG in any subcategory · reflecting reduced angina and increased physical capacity. The magnitude of improvement in NHP total score was >30%.
There were significant improvements in all four subcategories in QLQ-AP after intervention compared to run-in, but there was no significant difference between the CABG and the SCS group in any score.
According to Figs 1 and 2 there seems to be a deterioration during the postoperative observational period, between the second measuring point and the third. However, this change is not significant. The tendency seems to be general, i.e. none of the different subcategories can be identified as worsening significantly.
The 'pain' scores among the patients who have undergone CABG previously or within the study do not deviate significantly from the other patients at any of the three measuring points.
Survival data
Within 6 months after randomization, one patient in the SCS group and seven patients in the CABG group died (P<0·02). Three of the patients randomized to CABG died while waiting for the procedure [20] . At 3 and 5 years, there were no significant differences between the groups (Fig. 3) . Three years after randomization, 45 of 53 patients (84·9%) were alive in the SCS group, and 39 of 51 (76·5%) in the CABG group. After 5 years, 40 of 53 patients (75·5%) were alive in the SCS group, and 35 of 51 (68·6%) in the CABG group. Sixty-six percent of the deaths were cardiac deaths, without significant difference between the groups.
Additional follow-up data
The number of drugs taken at follow-up differs between the groups (Table 5) . However, the consumption of short-acting nitrates decreased in both groups.
The SCS treatment was generally well tolerated. During the follow-up time, three patients had their spinal cord electrodes surgically corrected. The stimulator had to be removed because of infection in one patient. No additional infections occurred in the SCS group. The average life span of the pulse generators before replacement was 3·6 years. 
Discussion
Both SCS and CABG provide clinically significant and long-lasting improvement in quality of life. These results reinforce the 6-month results in the ESBY study, where SCS and CABG both provided significant relief of anginal symptoms [20] . CABG gives no proven prognostic benefit in this patient group, but seems to be efficient in long-term symptom relief. Long-term follow-up of the newer treatment of SCS is important to ensure efficacy and safety, which seems to be in line with the outcome concerning quality of life and survival in the present study.
The magnitude of improvement in the NHP total score was >30% and reached a level comparable to that of a healthy population at the corresponding age [26] . Experiences from earlier studies imply that if the angina is relieved, the impaired quality of life will be normalized [28, 29] , and this appears to be true in the present study as well. This may also be the reason why all scores are significantly improved in the QLQ-AP, as this questionnaire is designed to measure changes directly related to the angina.
The placebo effect, which is present in all treatment methods, is mostly believed to subside with time [30] . In invasive treatments, the placebo effect is probably more prominent and extensive. However, a beneficial outcome 4-5 years after intervention seems to contradict the placebo effect as the main cause of improvement.
There seems to be a deterioration in the quality of life scores during the postoperative observational period, between the second measuring point and the third. However, this change is not significant. The cause of this change may primarily be a sign of angina relapse. However, the change in the 'pain' subcategory in the NHP questionnaire is not prominent. The tendency seems to be general, i.e. none of the different subcategories can be identified as worsening significantly.
It is known that a substantial proportion of patients who have undergone open heart surgery experience chronic scar pain. Twenty-five out of 104 patients included in the ESBY study had undergone CABG previously. However, the pain scores among the patients who had undergone CABG, previously or within the study, do not deviate significantly from the rest of the patients either at run-in or at any of the follow-up assessments.
Survival data should be considered of utmost importance in a discussion on treatment safety. In contrast to CABG, the SCS implantation is a minor surgical procedure, with negligible perioperative mortality risk. Early criticism of SCS in angina was that it would offer pain relief only, and thus increase the risk of silent ischaemic events. However, several studies from different centers have shown that ischaemia and infarction during stimulation give rise to typical pain, and the patient is not deprived of the warning signal [17] [18] [19] . In addition, experimental studies have shown that SCS has an antiischaemic effect, which is parallel to the antianginal effect [14] [15] [16] . Earlier clinical studies have not shown any increased risk of cardiac events or deaths among SCS-treated angina patients [12, 16, 19] . It is known from other studies that patients with stable angina pectoris suffer a mortality risk of 2-4% yearly [31] . Important earlier studies on mortality in pharmacologically treated angina populations are the Coronary Artery Surgery Study [32] , with an 8% mortality at 5 years, and the European Coronary Surgery Study [33] , with a 16·2% mortality at 5 years. The mortality in the ESBY patient group was higher than in these studies, but these populations do not match the ESBY patients with regard to age, presence of risk factors and severity of coronary vessel disease, and the studies were not performed during the same period of time.
In an investigation performed in Sweden by Brorson et al. at the Swedish Council on Technology Assessment in Health Care (SBU) in 1994-95, an angina subpopulation (n=186) with a similar extent of coronary artery disease as the ESBY patients and with pharmacological treatment had a mortality rate of 4·3% at 12 months and 9·1% at 21 months. This mortality rate does not differ significantly from that of the ESBY patients. This comparison is of interest, as a similar patient group was studied for the same period of time in the same country, thereby avoiding differences in diagnosis criteria and treatment, caused by time and geography.
The ESBY patients have, according to the inclusion criteria, additional risk factors compared to an average angina population. Within the AWESOME study [34] , performed in 1995-2000, 454 patients with medically refractory myocardial ischaemia and one or more risk factors for adverse outcomes with bypass were randomized to percutaneous coronary intervention (PCI) or CABG. The study population was comparable to the ESBY study concerning age, extent of coronary artery disease and presence of risk factors. Survival was assessed up to 36 months, and was 79% in the CABG group and 80% in the PCI group. This should be compared to the 3-year survival in the ESBY study (all patients 81%).
The number of drugs taken at follow-up differs significantly between the groups. On the other hand, the consumption of short-acting nitrates decreased significantly in both groups (Table 5 ). Cessation of beta-blockers, calcium antagonists and long-acting nitrates is common after CABG. As SCS is a newer and less well-documented treatment modality, medication that can be considered cardioprotective is always continued, if it causes no major side effects. The study protocol included no intervention concerning medication, i.e. the patients received medication according to the standard clinical care in each group. In the SCS group, the pharmacological treatment was virtually unchanged at follow-up. However, as this medication was insufficient to relieve the angina before the procedure, it can be assumed that SCS caused the marked relief of angina and the improvement in quality of life in this group.
There was no pharmacologically treated control group in the ESBY study, as the patients included were candidates for CABG, the standard clinical method of treatment. They were considered to be optimally medicated, but without satisfactory symptom relief.
In the randomized TIME study [35] , optimized medical therapy was compared to revascularization in 305 patients with chronic angina, aged 75 years or older. Due to patient age, a large proportion of the patients had risk factors and co-morbidity, (similar to the ESBY population). The revascularization group improved their quality of life significantly compared to the medically treated group, while there was no significant difference in survival -however, the follow-up time was limited to 6 months. The conclusion in the TIME study was that revascularization is also superior to pharmacological treatment also in patients at higher age and increased risk, while the results in the ESBY study suggest that SCS and revascularization (CABG) are comparable in a similar patient group.
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Conclusions
In parallel to the 6-month results concerning symptom relief in the ESBY study, spinal cord stimulation as well as coronary artery bypass grafting seem to offer significant and long-lasting improvement in quality of life in this patient group. Survival after 3 and 5 years was comparable between the groups. Taking into account the generally unhealthy patients included in the study -reflected by an average Higgin's score above 4 -the overall results are that a substantial proportion of the patients experience long-term survival and a high quality of life. Both SCS and CABG can be considered as effective treatment options for patients with severe angina, no anticipated prognostic benefit from revascularization and an increased surgical risk.
Study limitations
This study included a limited number of patients. Due to the inclusion criteria, only a small number of patients accepted for CABG were eligible for the study. Because of the rapid development of surgical and anaesthesiological methods, it was considered important to enrol patients over no more than 3 years, in order to render the entire study population suitable for comparative tests.
The surgical procedures compared in this study differ significantly from one another, and thus blinding was not possible.
No pharmacologically treated control group was included in the study.
